Among patients undergoing aortic valve replacement using a catheter tube, a comparison of two types of heart valve technologies, balloon-expandable or self-expandable valve systems, found a greater rate… read more.
The connection between being underweight and the higher risk of dying is true for both adults and foetuses. Being underweight puts people at highest risk of dying, just… read more.
Study helps put new TAVR technology in perspective for high-risk patients. The first one-year outcomes data of transcatheter heart valve replacement (TAVR) in nearly all U.S. patients undergoing… read more.
Applying the updated 2014 blood pressure (BP) guideline to the U.S. population suggests that nearly 6 million adults are no longer classified as needing hypertension medication, and that… read more.
Although some research has suggested that metformin, a medication often used in the treatment of diabetes, may have favourable effects on ventricular (heart) function, among patients without diabetes… read more.
The most frequently used mechanical circulatory assist device in the world may have untapped potential, physicians say. One of many uses for the intra-aortic balloon pump is helping… read more.
Heart problems less likely for spouses than for single, divorced and widowed people. People who are married have lower rates of several cardiovascular diseases compared with those who… read more.
Results of the study could help the 715,000 Americans who suffer from heart attacks each year. Researchers at the Intermountain Medical Center Heart Institute in Salt Lake City… read more.
Obese people who have stomach surgery to help them lose weight will halve their risk of heart attack according to new research from a team of doctors at… read more.
A comparison of the safety of biodegradable polymer biolimus-eluting stents vs durable polymer everolimus-eluting stents finds similar outcomes for measures including death and heart attack after two years,… read more.
The 6-month follow-up data from the METOCARD-CNIC trial are published in the Journal of the American College of Cardiology.
Use of the drug aleglitazar, which has shown the ability to lower glucose levels and have favorable effects on cholesterol, did not reduce the risk of cardiovascular death,… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
